Vincerx Pharma, Inc.

VINC

US92731L1061

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-31 EDT			5-day change	1st Jan Change
0.631 ^USD	-9.57%		-7.72%	-46.53%

04-26	Tech Rally Boosts Exchange-Traded Funds, Equity Futures Pre-Bell Friday	MT
04-26	Vincerx Pharma Prices Public Offering of Shares, Warrants	MT

Vincerx Pharma, Inc. Announces Departure of Hermes Garban as Chief Medical Officer, Effective on or Before August 6, 2022

June 07, 2022 at 04:02 pm

Vincerx Pharma, Inc. announced that In connection with the strategic plan, Hermes Garban, M.D., Ph.D., will depart from his role as the company's Chief Medical Officer on or before August 6, 2022.

Latest news about Vincerx Pharma, Inc.

Tech Rally Boosts Exchange-Traded Funds, Equity Futures Pre-Bell Friday	04-26	MT
Vincerx Pharma Prices Public Offering of Shares, Warrants	04-26	MT
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	04-09	MT
Top Premarket Decliners	04-09	MT
Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell	04-09	MT
Vincerx Pharma, Inc. Presents Positive Preliminary Phase 1 Data for Vip236 and Updates on Pipeline Progress At the American Association for Cancer Research Annual Meeting 2024	04-08	CI
Vincerx Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
North American Morning Briefing : Tech in Focus on -2-	03-25	DJ
Vincerx Pharma Shares Jump After Results of Blood Cancer Treatment Trial	01-08	MT
Top Premarket Gainers	01-08	MT
Vincerx Pharma, Inc. Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma	01-07	CI
Vincerx Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Sector Update: Health Care Stocks Mixed Premarket Thursday	23-09-14	MT
Vincerx Pharma Doses First Patient in Early-Stage Trial of Blood Cancer Drug Candidate	23-09-14	MT
Sector Update: Health Care Stocks Slipping Late Afternoon	23-08-22	MT
Sector Update: Health Care Stocks Lower in Afternoon Trading	23-08-22	MT
Vincerx Pharma Says US FDA Approved Phase 1 Trial for Potential Acute Myeloid Leukemia Treatment	23-08-22	MT
Vincerx Pharma Shares Jump 8% Premarket After FDA Clearance for Clinical Trial	23-08-22	DJ
Vincerx Pharma, Inc. Announces FDA Clearance of IND for VIP943	23-08-22	CI
Vincerx Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Vincerx Pharma, Inc.(NasdaqCM:VINC) dropped from Russell 3000E Value Index	23-06-23	CI
Vincerx Pharma, Inc.(NasdaqCM:VINC) dropped from Russell Microcap Index	23-06-23	CI
Vincerx Pharma, Inc.(NasdaqCM:VINC) dropped from Russell Microcap Value Index	23-06-23	CI
Vincerx Pharma, Inc.(NasdaqCM:VINC) dropped from Russell 3000E Index	23-06-23	CI
Vincerx Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI

Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. It has a next generation bioconjugation platform, called VersAptx. The VersAptx platform is a versatile and adaptable, next generation bioconjugation platform. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (P-TEFb/CDK9 inhibitor). VIP943 is a potential anti-CD123 ADC created with its VersAptx Platform. It consists of an anti-CD123 antibody, a novel legumain-cleavable linker, and a KSPi payload enhanced with its CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.631 USD

Average target price

9 USD

Spread / Average Target

+1,326.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VINCERX PHARMA, INC.	-46.53%	18.64M
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	+0.09%	21.96B
GENMAB A/S	-8.24%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B
INSMED INCORPORATED	+77.64%	8.87B

Bio Therapeutic Drugs